Oruka Therapeutics 株価情報 (NASDAQ: ORKA)

最新ニュース Oruka Therapeutics (NASDAQ:ORKA) 株価情報

Oruka Therapeutics

Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.

Oruka Therapeutics Inc

Elanco Animal Health Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY&#xAE; (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit &amp; Insurance for $295 million in cash. Monetization of this non-core asset will be used to accelerate debt reduction, positioning Elanco to achieve an expected net leverage ratio of 3.9x to 4.3x adjusted EBITDA by the end of 2025. Elanco will repay portions of its outstanding term loans on a pro-rata basis, which is expected to reduce interest expense by approximately $10 million, offset by the sale of approximately $10 million of royalties based on Elanco's initial 2025 guidance.
&nbsp;
In 2019, Elanco exclusively licensed lotilaner to Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) for exploration as a solution to several unmet human health needs. In 2023, XDEMVY became the first lotilaner-based product approved for human use and the only FDA-approved medicine for treatment of Demodex blepharitis (DB), a common eyelid disease in humans caused by Demodex mites.

News

ELAN

TARS

Elanco Monetizes XDEMVY Royalties in $295M Deal to Lower Debt and Reduce Interest Costs

HC Wainwright &amp; Co. analyst Scott Buck maintains Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) with a Neutral and raises the price target from $1 to $1.5.

Price Target

Analyst Ratings

INTZ

HC Wainwright & Co. Maintains Neutral on Intrusion, Raises Price Target to $1.5

U.S. stock futures fell on Monday after a nine-day winning streak on the S&amp;P 500 index. Futures of major benchmark indices were lower in premarket.
The S&amp;P 500 index notched a nine-day advance for the first time since November 2004 on Friday.
While aboard Air Force One, Donald Trump confirmed U.S. officials are <a href="https://www.benzinga.com/news/global/25/05/45188171/china-pushes-for-special-envoys-as-direct-deal-with-trump-deemed-risky-plans-fentanyl-concessions-as-negotiating-leverage-report">engaged in trade discussions</a> with Chinese counterparts, though he has no planned meeting with President Xi Jinping this week. 
While the Chinese have proposed the concept of special envoys, the U.S. is reluctant, favoring direct negotiations between Trump and Xi. However, the Chinese view this proposal as "risky and uncertain", <a href="https://www.scmp.com/news/china/diplomacy/article/3308919/us-china-trade-stand-ease-negotiators-must-be-agreed-upon-analysts">reported</a> the South China Morning Post.
Investors will also keep an eye on the Federal Reserve&#8217;s decision on interest rates this week.
Meanwhile, the 10-year Treasury bond yielded 4.31% and the two-year bond was at 3.82%. The CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>&#8216;s projections show markets pricing a 98.2% likelihood of the Federal Reserve keeping the current interest rates unchanged in its May meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.66%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.77%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.89%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.88%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell in premarket on Monday. The SPY was down 0.70% to $562.82, while the QQQ declined 0.84% to $484.74, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Bolstered by strong performances in financial, communication services, and industrial stocks on Friday, U.S. markets finished the week higher for all major averages.
The S&amp;P 500, which recorded its ninth consecutive day of gains, the longest since Nov. 2004, and added 2.9% for the week, saw contrasting movements with health care and consumer staples declining on Friday. The Dow gained 3% and the Nasdaq rose 3.4% for the week.
After the end of the nine-day streak, the S&amp;P 500 index was out of the correction zone, just down 7.5% from its record high of 6,147.43 points, scaled on Feb. 19. Dow Jones was 8.33% lower than its 52-week high of 45,073.63 points and Nasdaq 100 was 9.54% lower than its previous high of 22,222.61 points.
Strong jobs data and rising factory orders buoyed the market. Nonfarm payrolls exceeded forecasts at 177,000, easing tariff-related hiring concerns, while the unemployment rate held steady at 4.2%. Additionally, new orders for U.S.-manufactured goods jumped 4.3% in March to $618.8 billion.
The Dow Jones index jumped 565 points or 1.39% to 41,317.43, whereas the S&amp;P 500 index surged 1.47% to 5,686.67. Nasdaq Composite ended 1.51% higher at 17,977.73, and the small-cap gauge, Russell 2000, also advanced 2.27% to 2,020.74.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.51%</td>
<td>17,977.73</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>1.47%</td>
<td>5,686.67</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.39%</td>
<td>41,317.43</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2.27%</td>
<td>2,020.74</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
According to Brian Therien, the investment strategist at Edward Jones, the process of completing a U.S.-China trade deal would likely be complex and lengthy. &#8220;Any de-escalation in trade tensions should be positive for the economy and financial markets, in our view,&#8221; he said.
The solid labor market should allow the Fed to remain on hold a while longer, said Therien, as it will help the Fed to gain greater clarity on the impact of tariffs on inflation.
&#8220;Bond markets have pushed back expectations for the next Fed funds rate cut to July, from June, though total rate cuts priced in for this year remain in the 3-4 range,&#8221; he said.
&#8220;Wider earnings growth should drive more balanced market performance across sectors, strengthening the case for portfolio diversification, in our view,&#8221; he said about corporate earnings.
Ryan Detrick from Carson Research highlighted that the S&amp;P 500 has witnessed seven other nine-day winning streaks over the last 40 years.
&#8220;Only once did the economy move into a recession within six months, and that was in 1990 when oil spiked due to Iraq invading Kuwait,&#8221; he highlighted.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Going back 40 years there have been seven other 9-day win streaks for the S&amp;P 500. Only once did the economy move into a recession within six months and that was in 1990 when oil spiked due to Iraq invading Kuwait.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1919227797169381422?ref_src=twsrc%5Etfw">May 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on this week:
<ul>
<li>On Monday, the S&amp;P final U.S. services PMI for April will be out by 9:45 a.m., and ISM services data for April will be released by 10:00 a.m. ET.</li>
<li>On Tuesday, the U.S. trade deficit data for March will be out by 8:30 a.m.</li>
<li>On Wednesday, the FOMC meeting will begin at 2:00 p.m., and Fed Chairman Jerome Powell will deliver the verdict at a press conference at 2:30 p.m. ET.</li>
<li>Consumer credit for March will be out by 3:00 p.m. ET.</li>
<li>On Thursday, initial jobless claims for the week ended May 3 and U.S. productivity data for the first quarter will be released by 8:30 a.m. ET.</li>
<li>March&#8217;s wholesale inventories data will be out by 10:00 a.m. ET.</li>
<li>On Friday, Fed Governor Michael Barr will speak at 5:55 a.m., New York Fed President John Williams will speak at 6:15 a.m., and Fed Governor Adriana Kugler will speak at 6:45 a.m. ET.</li>
<li>Fed Governor Lisa Cook will speak at 6:45 a.m. ET.</li>
<li>Richmond Fed President Tom Barkin speaks at 8:30 a.m., Fed Governor Christopher Waller and New York Fed President John Williams will speak on a panel at 11:30 a.m. ET.</li>
<li>Fed Governor Michelle Bowman, St. Louis Fed President Alberto Musalem, and Fed Cleveland President Beth Hammack will speak on a panel at 7:45 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Tyson Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) rose 2.78% in premarket on Monday as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of 82 cents per share on revenue of $13.14 billion.</li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) was 0.5% higher as Wall Street expects it to report earnings of $4.90 per share on revenue of $8.19 billion before the opening bell.</li>
<li>Transcode Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) dropped 21.67% after announcing a 1-for-28 reverse stock split.</li>
<li>Henry Schein Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) fell 1.36% as it is expected to report earnings before the opening bell. Analysts expect a quarterly earnings of $1.11 per share on revenue of $3.23 billion.</li>
<li>Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) declined 0.19% as Wall Street expects it to report earnings of 2 cents per share on revenue of $36.20 billion after the closing bell.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFAI#NASDAQ">FFAI</a>) rose 5.98% after it announced an additional significant pre-order for its FX Super One MPV, adding 300 Units in another B2B Agreement.</li>
<li>Bon Natural Life Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BON#NASDAQ">BON</a>) slumped 13.08% after it received a delisting notice as the stock crashed below 10 cents.</li>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) jumped 18.81% as trading on a post-split basis began on May 5.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 1.58% to hover around $57.37 per barrel.
Gold Spot US Dollar rose 1.65% to hover around $3,294.46 per ounce. Its last record high stood at $3,305.13 per ounce. The U.S. Dollar Index spot was lower by 0.39% at the 99.6370 level.
Asian markets were mixed on Monday. China&#8217;s CSI 300 and Australia's ASX 200 indices declined. While Hong Kong's Hang Seng, Japan's Nikkei 225, India's S&amp;P BSE Sensex, and South Korea's Kospi index rose. European markets were also mixed in early trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45188341/billionaire-mark-cuban-asks-if-small-businesses-be-ignored-after-trump-redirects-question-on-tariff-relief-for-little-businesses">Billionaire Mark Cuban Asks Should Small Businesses Be &#8216;Ignored&#8217; After Trump Redirects Question On Tariff Relief For &#8216;Little Businesses&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

Futures

Economics

Federal Reserve

Pre-Market Outlook

Markets

Trading Ideas

Faraday Future Intelligent Electric Inc. - Class A Common Stock

FFAI

HSIC

PLRZ

RNAZ

US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert

HC Wainwright &amp; Co. analyst Amit Dayal reiterates NPK International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NYSE">NPKI</a>) with a Buy and maintains $12 price target.

Reiteration

NPKI

HC Wainwright & Co. Reiterates Buy on NPK International, Maintains $12 Price Target

Fund manager Dan Niles suggests the recent stock market rally may be running out of steam as pull-forward demand artificially boosted first-quarter results and economic uncertainties mount.
What Happened:&nbsp; Niles, founder of Niles Investment Management, shared on X that the S&amp;P 500, as tracked by&nbsp;SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) has rallied 14% from its April 8 lows through May 2, driven by &#8220;better than feared guidance during earnings season and hopes of 90 trade deals in 90 days.&#8221;
However, he now believes &#8220;there is not much upside left to this rally,&#8221; noting troubling signs as even strong performers like Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) declined on Friday despite beating quarterly expectations.
&#8220;It would not surprise me if the actual announcements turned into sell the news events,&#8221; Niles wrote. 
Niles highlighted the staggering 41% year-over-year increase in imports reported in first-quarter Gross Domestic Product data, suggesting significant demand pull-in ahead of tariffs that &#8220;will eventually need to be paid back in future quarters.&#8221;
He drew parallels to previous bear market rallies, noting the S&amp;P had 11 rallies of 10% on average during the Global Financial Crisis while ultimately losing 57% over 18 months.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">While I started the year with cash as my leading pick given my concerns entering the year, on April 7th I did a CNBC interview that was titled "Might see a short-term bounce, but still cautious long-term, says investor Dan Niles." On April 9th, the 90 day pushback on tariffs by…
&mdash; Dan Niles (@DanielTNiles) <a href="https://twitter.com/DanielTNiles/status/1919186444301508709?ref_src=twsrc%5Etfw">May 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/markets/equities/25/05/45188268/palantir-climbs-above-126-in-overnight-robinhood-trading-so-many-bears-out-there-says-lawrence-mcdonald">Palantir Climbs Above $126 In Overnight Robinhood Trading: &#8216;So Many Bears Out There,&#8217; Says Lawrence McDonald</a>
Why It Matters:&nbsp;The market slide could present a buying opportunity for a &#8220;<a href="https://www.benzinga.com/25/03/44135699/big-tech-slide-an-opportunity-to-buy-amid-selloff-analyst-highlights-bigger-fundamental-concerns-amid-the-possibility-of-technical-bounce-back">technical bounce back</a>,&#8221; though Niles maintains &#8220;fundamental concerns for the longer-term,&#8221; according to his previous statements.
With the S&amp;P&#8217;s trailing price-to-earnings ratio now at 24 times and economic uncertainty &#8220;higher today than back then,&#8221; Niles believes earnings estimates will ultimately decline for the second half of 2025.
Niles previously excluded all &#8220;Magnificent 7&#8221; tech giants from his top stock picks for 2025, citing &#8220;disappointing first-quarter earnings outlook&#8221; among his reasons.
He also pointed to Berkshire Hathaway Inc. growing its cash position to $348 billion while being a net seller of stocks for 10 straight quarters, reflecting &#8220;caution also on Warren Buffett&#8216;s part.&#8221;
Among tech leaders, Niles <a href="https://www.benzinga.com/25/03/44135699/big-tech-slide-an-opportunity-to-buy-amid-selloff-analyst-highlights-bigger-fundamental-concerns-amid-the-possibility-of-technical-bounce-back">has previously noted</a> that &#8220;&#8216;Magnificent 7&#8217; tech giants have fallen from grace in 2025.&#8221; 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/05/45188171/china-pushes-for-special-envoys-as-direct-deal-with-trump-deemed-risky-plans-fentanyl-concessions-as-negotiating-leverage-report">China Pushes For Special Envoys As Direct Deal With Trump Deemed &#8216;Risky&#8217;, Plans Fentanyl Concessions As Negotiating Leverage: Report</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with&nbsp;the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was&nbsp;reviewed and published by Benzinga editors.

Opinion

Tech

AAPL

AMZN

MSFT

NVDA

S&P Rally May Be Topping Out, Dan Niles Warns, Amid Demand Pull-In, Economic Uncertainty, And 'Sell The News' Risk

The Milken Institute's 28th annual Global Conference began on Sunday and will run through May 7 at the Beverly Hilton in Los Angeles.
What Happened: Held under the theme &#8220;Toward a Flourishing Future,&#8221; the event features more than 1,000 speakers and 5,000 attendees from over 80 countries, including CEOs, policymakers, scientists, philanthropists, and cultural icons.
Among the high-profile attendees this year are Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) CEO Jensen Huang, former basketball player Magic Johnson, actor Patrick Dempsey, X Corp. CEO Linda Yaccarino, former First Lady Jill Biden, Ford Philanthropy President Mary Culler, Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) CEO Robert Ford and Citadel LLC founder Ken Griffin.
See Also:&nbsp;<a href="https://www.benzinga.com/25/04/45093311/not-everyone-needs-a-thousand-ai-engineers-but-for-those-who-do-zuckerberg-says-meta-will-gladly-build-it-for-a-price" target="_blank" rel="noreferrer noopener">Meta CEO Mark Zuckerberg Says AI Won't Just Be About Free Tools And Ads — Some People Will Pay A Fortune To Deploy Armies Of Digital Workers</a>
From closed-door roundtables to public panels, attendees are engaging in discussions on artificial intelligence, climate resilience, healthcare innovation, income inequality, and women's health, among other pressing issues.
A Recap Of 2024: Last year at the conference, in a session with Mike Milken, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk spoke <a href="https://www.benzinga.com/news/24/05/38666652/tech-billionaire-elon-musk-reveals-the-3-things-that-keep-him-up-at-night-and-one-thing-that-is-his">about his top concerns</a>, including declining birth rates, threats to democracy, and the erosion of merit-based systems.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Another headline-making moment was when billionaire investor Bill Ackman came <a href="https://www.benzinga.com/news/24/05/38754804/billionaire-investor-bill-ackman-grilled-by-wall-street-executives-for-anti-dei-views-report">under sharp criticism from</a> top Wall Street executives for his opposition to diversity, equity, and inclusion initiatives during a closed-door session at the Milken Institute Global Conference.
OpenAI COO Brad Lightcap also attended the event last year and used the stage to <a href="https://www.benzinga.com/news/24/05/38661631/chatgpt-is-not-a-long-term-engagement-model-openais-top-executive-says-todays-systems-are-laughably">forecast a new wave of AI tools</a> that will act less like static oracles and more like dynamic, intelligent teammates.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/07/39842841/charlie-munger-said-getting-rich-is-harder-than-ever-but-heres-the-beauty-of-it-you-only-have-to" target="_blank" rel="noreferrer noopener">Charlie Munger Said Getting Rich Is Harder Than Ever, But Here&#8217;s ‘The Beauty Of It&#8217; — You Only Have To Do It Once</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo Courtesy: jamesonwu1972 On Shutterstock.com

TSLA

Jensen Huang, Magic Johnson, Patrick Dempsey, Linda Yaccarino And More Bigwigs Headline Milken Global Conference 2025: What You Need To Know

<a href="https://www.globenewswire.com/Tracker?data=jj2k1axtY2maqvBm3y4KvOMgk_NoOknRG4izqbr7DT7JGV2fyentA-uK2p11qU08W0_T_bf8AjIEaC7p0GD8fA==">Aclarion, Inc</a>., ("Aclarion" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/ACON#NASDAQ">ACON</a>, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the addition of <a href="https://www.globenewswire.com/Tracker?data=PZpCJtoIDTx_ZAznUqUwWvda7xOA90jl_zrii9kngZkNXA9oaJvrJbLRzdu5OFXgGI9nbRlCmCOQQiZKLx2z4CYrTj8WGlytOiU1gAqn6s26ojp88kxNDNkkp5m_HbMML5qw44UFScj4gQSUnwa399Voan2ktkAFNHi9lcPWqnw=">Advocate Aurora Research Institute</a>, part of Advocate Health, as a CLARITY (Chronic&nbsp;Low bAck pain&nbsp;Randomized&nbsp;Independent&nbsp;Trial studY) site. CLARITY is a pivotal, randomized trial designed to demonstrate Nociscan's clinical and economic value in spine surgery.

ACON

Aclarion Expands CLARITY Trial with Advocate Aurora Research Institute to Improve Chronic Back Pain Diagnosis

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Ffullscript.com%2F%3Futm_medium%3Dpress-release&amp;esheet=54248595&amp;newsitemid=20250505216112&amp;lan=en-US&amp;anchor=Fullscript&amp;index=1&amp;md5=08d27702b79a16b383653a2525db4920">Fullscript</a>, a leading healthcare platform powering whole person care, today announced an expanded investment from HGGC, a leading middle-market private equity firm, and Snapdragon Capital Partners ("Snapdragon") to support its next phase of growth. The new capital, supported by a continuation vehicle led by Leonard Green &amp; Partners as the sole lead investor, underscores strong investor confidence in Fullscript's innovative model and long-term market leadership. HGGC, with Snapdragon as a minority investor, originally invested in Fullscript in 2021.

XPOF

Fullscript Secures Expanded Investment to Fuel Next Phase of Growth in Healthcare Innovation

Legal

Reuters Reported US Rep Bill Foster (D-IL) Plans Bill To Track AI Chips After Sale To Curb Smuggling Of NVIDIA And Other AI Hardware Into China

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jumio.com%2F&amp;esheet=54248293&amp;newsitemid=20250505397831&amp;lan=en-US&amp;anchor=Jumio&amp;index=1&amp;md5=bf0dbd5e1948b50064d06813fa39734c">Jumio</a>, the leading provider of automated, AI-driven biometric identity verification, risk signals and compliance solutions, has partnered with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.alaskaair.com%2F&amp;esheet=54248293&amp;newsitemid=20250505397831&amp;lan=en-US&amp;anchor=Alaska+Airlines&amp;index=2&amp;md5=d4df35f4c8d4e1912cdc362379902654">Alaska Airlines</a> to make check-in easier than ever for international travelers.
Alaska Airlines is committed to providing its guests with a caring and seamless travel experience. This has led the airline to pursue innovations that enhance guests' experience throughout the travel process, from the time they are searching for flights to their day of travel. As part of this effort, Alaska has invested in redefining its check-in experience, with an emphasis on self-service, digital offerings that minimize time spent in the airport lobby, helping guests get to security in five minutes or less.
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.jumio.com%2Fproducts%2Fid-verification%2F&amp;esheet=54248293&amp;newsitemid=20250505397831&amp;lan=en-US&amp;anchor=Jumio+ID+Verification&amp;index=3&amp;md5=e4f203215443aa471b5cae49dd1927e2">Jumio ID Verification</a> is now fully integrated into the Alaska Airlines mobile app, enabling international travelers with U.S. and Canadian passports to verify their identity without standing in line at the check-in counter. This allows Alaska Airlines to establish the genuine identity of their guests — both individual travelers and multi-passenger itineraries — by verifying government-issued IDs in real time, automatically. Jumio offers the most comprehensive ID verification solution on the market, accepting and reliably verifying multiple types of government-issued IDs including passports, driver's licenses and ID cards. In total, Jumio supports more than 5,000 ID subtypes around the globe.

Alaska Airlines Partners with Jumio to Streamline International Check-In for Faster, Seamless Travel

An expansion of Consumers Energy's Zeeland natural gas plant is underway and anticipated to be complete mid-June prior to the summer peak generation period, reinforcing the company's long-standing commitment to delivering reliable, affordable and flexible energy to Michigan communities. This investment is part of Consumers Energy's broader <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4419226-1&amp;h=155165433&amp;u=https%3A%2F%2Fwww.consumersenergy.com%2Fabout-us%2Fwho-we-are%2Fworld-class-performance&amp;a=Reliability+Roadmap">Reliability Roadmap</a>, a strategic initiative focused on modernizing infrastructure and enhancing grid resilience to prepare for Michigan's energy future.

Consumers Energy Invests in Zeeland Plant Expansion to Strengthen Michigan's Energy Grid for the Future

JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) is looking for Q2 GAAP EPS of $0.20-$0.40 vs $0.42 analyst estimate..

Guidance

JBTM

JBT Marel Sees Q2 GAAP EPS $0.20-$0.40 vs $0.42 Est

JBT Marel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBTM#NYSE">JBTM</a>) is looking for Q2 Adj EPS of $1.20-$1.40 vs $1.26 analyst estimate. sees sales of $885.000 million-$915.000 million vs $876.64 million analyst estimate.

JBT Marel Sees Q2 Adj EPS $1.20-$1.40 vs $1.26 Est; Sees Sales $885.000M-$915.000M vs $876.64M Est

Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) reported quarterly earnings of $1.09 per share which beat the analyst consensus estimate of $0.95 by 14.74 percent. This is a 36.25 percent increase over earnings of $0.80 per share from the same period last year. The company reported quarterly sales of $816.99 million which missed the analyst consensus estimate of $906.77 million by 9.90 percent. This is a 18.80 percent increase over sales of $687.69 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

ARES

Ares Management Q1 Adj. EPS $1.09 Beats $0.95 Estimate, Sales $816.99M Miss $906.77M Estimate

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) affirms FY2025 Adj EPS guidance from $4.80-$4.94 to $4.80-$4.94 vs $4.86 analyst estimate. Affirms FY2025 sales outlook from $12.43 billion-$13.18 billion to $12.43 billion-$13.18 billion vs $13.00 billion estimate.

Henry Schein Affirms FY2025 Adj EPS Guidance of $4.80-$4.94 vs $4.86 Est; Affirms FY2025 Sales Guidance of $12.43B-$13.18B vs $13.00B Est

Loews (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>) reported quarterly earnings of $1.74 per share. This is a 15.12 percent decrease over earnings of $2.05 per share from the same period last year. The company reported $4.49 billion in sales this quarter. This is a 6.22 percent increase over sales of $4.23 billion the same period last year.

Loews Q1 EPS $1.74 Down From $2.05 YoY, Sales $4.49B Up From $4.23B YoY

Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.52) by 3.85 percent. This is a 28.21 percent decrease over losses of $(0.39) per share from the same period last year. The company reported quarterly sales of $14.74 million which missed the analyst consensus estimate of $18.12 million by 18.61 percent. This is a 9.30 percent increase over sales of $13.49 million the same period last year.

RXRX

Recursion Pharmaceuticals Q1 EPS $(0.50) Beats $(0.52) Estimate, Sales $14.74M Miss $18.12M Estimate

Escalade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESCA#NASDAQ">ESCA</a>) reported quarterly earnings of $0.19 per share. This is a 46.15 percent increase over earnings of $0.13 per share from the same period last year. The company reported $55.48 million in sales this quarter. This is a 3.18 percent decrease over sales of $57.30 million the same period last year.

ESCA

Escalade Q1 EPS $0.19 Up From $0.13 YoY, Sales $55.48M Down From $57.30M YoY

CNA Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNA#NYSE">CNA</a>) reported quarterly earnings of $1.03 per share which missed the analyst consensus estimate of $1.14 by 9.65 percent. This is a 20.77 percent decrease over earnings of $1.30 per share from the same period last year. The company reported quarterly sales of $3.63 billion which beat the analyst consensus estimate of $3.07 billion by 18.14 percent. This is a 5.31 percent increase over sales of $3.44 billion the same period last year.

CNA Financial Q1 Adj. EPS $1.03 Misses $1.14 Estimate, Sales $3.63B Beat $3.07B Estimate

Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) reported quarterly earnings of $1.15 per share which beat the analyst consensus estimate of $1.11 by 3.6 percent. This is a 4.55 percent increase over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $3.17 billion which missed the analyst consensus estimate of $3.23 billion by 1.83 percent. This is a 0.13 percent decrease over sales of $3.17 billion the same period last year.

Comments

Oruka Therapeutics

ニュース

最新ニュース Oruka Therapeutics (NASDAQ:ORKA) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル